ClinicalTrials.gg
RecruitingNCT07595874NEST3Updated Oct 19, 2026

Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3

A Phase 2 interventional study of Balstilimab and Biospecimen Collection in Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma and Advanced Rectal Adenocarcinoma, sponsored by City of Hope Medical Center. Recruiting at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by City of Hope Medical Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 19, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Colonic Neoplasms by City of Hope Medical Center — 6 open to participants now, 9 under way, none of them phase 3. Colonic Neoplasms · City of Hope Medical Center.

Planned enrollment
4th of 24
100 · median 20
Started
2026
the only one that year
Phase 2
7 of 30
3 open now
Registered
30th of 30
by date

Among the 30 studies in Colonic Neoplasms by City of Hope Medical Center, this one is the 4th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2026, is one of 7 in phase 2, and was the 30th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

6 of the 30 studies in Colonic Neoplasms by City of Hope Medical Center are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Colonic Neoplasms by City of Hope Medical Center, or all of them as a file.
02

Study summary

This phase II trial tests how well giving botensilimab and balstilimab prior or to surgery (neoadjuvent) works for the treatment of colorectal cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that can be removed by surgery (resectable) colorectal cancer. Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving botensilimab and balstilimab before surgery may make the tumor smaller. Giving neoadjuvant botensilimab and balstilimab may be effective for the treatment of advanced resectable colorectal cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To estimate the two-year disease-free survival (DFS) rate when treating advanced mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer with botensilimab (BOT)/balstilimab (BAL) followed by surgery.

SECONDARY OBJECTIVES:

I. To determine the major pathologic response rate for patients with advanced mismatch repair proficient or microsatellite stable (pMMR or MSS) colorectal cancer treated with botensilimab (BOT) + balstilimab (BAL) followed by surgery.

II. To evaluate the safety of treating advanced pMMR/MSS colorectal cancer with BOT/BAL followed by surgery.

III. To estimate the pathologic response rate when treating advanced pMMR/MSS colorectal cancer with BOT/BAL followed by surgery.

IV. To estimate the three-year disease-free survival rate when treating advanced pMMR/MSS colorectal cancer with BOT/BAL followed by surgery.

V. To estimate the median recurrence free survival in patients with advanced pMMR/MSS colorectal cancer with BOT/BAL followed by surgery, among patients who are disease free at the time of surgery.

VI. To describe the proportion of patients that get all four doses of BAL. VII. To describe the quality of life of patients with advanced pMMR/MSS colorectal cancer with BOT/BAL followed by surgery.

VIII. To describe the time to surgery after treating advanced pMMR/MSS colorectal cancer with BOT/BAL followed by surgery.

IX. To describe the percent of pMMR/MSS colorectal cancer patients treated with BOT/BAL followed by surgery in which adjuvant therapy is recommended, amount and type received, as well as patient refusal rate.

EXPLORATORY OBJECTIVES:

I. To examine changes in tumor microenvironment in response to BOT/BAL when treating advanced pMMR/MSS colorectal cancer.

II. To explore the serial changes in circulating tumor deoxyribonucleic acid (ctdna) when treating advanced pMMR/MSS colorectal cancer with BOT/BAL followed by surgery.

III. To explore markers on baseline imaging that correlate with response and long-term outcomes.

IV. To determine ctDNA and cell free deoxyribonucleic acid (cfDNA) detectability before, during and after neoadjuvant BOT/BAL and curative-intent surgical resection.

V. To describe the association between detectable ctDNA and cfDNA measured before, during and after neoadjuvant post-neoadjuvant treatment and surgery with DFS and pathologic response.

VI. To describe the difference in time between ctDNA and cfDNA detection (molecular recurrence) and radiographic evidence of disease recurrence following definitive treatment among patients who achieved undetectable ctDNA and/or cfDNA levels after surgery.

VII. Among patients that get presurgical standard of care (SOC) imaging, to describe the presurgical radiologic response.

OUTLINE:

Patients receive botensilimab intravenously (IV), over 30 minutes, on day 1 and balstilimab IV, over 30 minutes, on days 1, 15, 29 and 43 in the absence of disease progression or unacceptable toxicity. 5-16 weeks later, patients then undergo standard of care resection surgery. Patients undergo computed tomography (CT) scan and/or magnetic resonance imaging (MRI) and blood sample collection throughout the study.

After completion of study treatment, patients are followed up at 2 weeks, 4 weeks and every 3 months for 2 years then every 6 months for 1 year.

03

Conditions studied

  • Advanced Colon Adenocarcinoma
  • Advanced Colorectal Adenocarcinoma
  • Advanced Rectal Adenocarcinoma
  • Stage IIB Colon Cancer AJCC v8
  • Stage IIB Rectal Cancer AJCC v8
  • Stage IIC Colon Cancer AJCC v8
  • Stage IIC Rectal Cancer AJCC v8
  • Stage IIIA Colon Cancer AJCC v8
  • Stage IIIA Rectal Cancer AJCC v8
  • Stage IIIB Colon Cancer AJCC v8
  • Stage IIIB Rectal Cancer AJCC v8
  • Stage IIIC Colon Cancer AJCC v8
  • Stage IIIC Rectal Cancer AJCC v8
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and Legally Authorized Representative (when applicable)

    • Assent, when appropriate, will be obtained and documented for adults lacking capacity per institutional guidelines
  • Agreement to allow the use of tissue from past and future surgery and standard of care
  • Age: ≥ 18 years
  • (ECOG) ≤ 2
  • confirmed or cytologically confirmed colorectal adenocarcinoma. Patients with high grade dysplasia on histology plus unequivocal endoscopic or radiological evidence of invasive cancer are eligible.

Patients diagnosed with rectal cancer who will be treated like colon cancer with curative-intent surgery first and no radiation are also eligible, including:

  • Upper rectum or rectosigmoid considered as non-rectal and not undergoing treatment
  • The tumor component should not extend to less 12 cm from the anal verge.
  • Any patient with rectal cancer for whom radiotherapy is not advised is included in this protocol (i.e., excluding rectal adenocarcinomas warranting treatment with chemoradiation)

    • Microsatellite stability by mismatch repair by immunohistochemistry, polymerase chain reaction and/or other Clinical Laboratory Improvement Amendments (CLIA) certified next generation sequencing. Only patients with mismatch repair proficient or microsatellite stable (pMMR/MSS) tumors are allowed to enroll in the study
    • Candidate for and planning a curative resection. Must have surgeon identified
    • T4, N+ (American Joint Committee on Cancer [AJCC] TNM staging criteria), or both by central radiographic assessment.
  • Note: Patients with T3N0 stage IIA are excluded. Stage IIB, IIC, IIIA, IIIB, and IIIC are included. Patients with stage IV disease are excluded

    • (ANC) ≥ 1,500/mm\^3
    • ≥ 75,000/mm\^3
  • NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment

    • ≥ 8 g/dL
  • NOTE: Red blood cell transfusions are permitted. Patients should not have active bleeding requiring regular transfusions. Iron infusions are also allowed

    • Total ≤ 1.5 X (ULN) (unless has Gilbert's disease, in which case the liver function tests must meet the other eligibility in the protocol)
    • (AST) ≤ 3.0 x ULN
    • Alanine aminotransferase (ALT) ≤ 3.0 x ULN
    • of ≥ 40 mL/min per the Cockcroft-Gault formula
    • Women of (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
    • Agreement by females and males of childbearing potential* to use an effective method of or abstain from heterosexual activity for the course of the study through at least 9 months for women, and at least 6 months for men, after the last dose of oxaliplatin therapy. If patients discontinue oxaliplatin more than 9 months (females) or 6 months (males) before discontinuation of balstilimab and/or botensilimab, females and males of childbearing potential must use an effective method of birth control or abstain from sexual activity for the course of the study through at least 120 days after the last dose of balstilimab and/or botensilimab.
  • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only).
  • The following are acceptable birth control methods for this study: Surgical sterilization (tubal ligation or hysterectomy for women, or vasectomy for men), double-barrier methods (i.e. condoms, diaphragm, cervical cap, or sponge, used together with spermicidal gel or foam), intrauterine device (IUD) (i.e. Progestin, Copper), or hormonal contraceptives (birth control patches, implants, pills, rings, or injections)

Exclusion criteria

Exclusion Criteria:

  • Any treatment for colorectal cancer prior to enrollment that includes (but not limited to) chemotherapy, surgery, radiation, immunotherapy and/or biological therapy.

    • Note: Surgical intervention e.g. a diverting ostomy to relieve an obstruction from colorectal cancer, those patients will be allowed to enter the study as long as no distant disease
  • Patients with a condition requiring systemic treatment with either (> 10 mg daily prednisone equivalent) within 14 days or another medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active disease
  • Prior allogeneic organ transplantation
  • Herbal medications that require a prescription or are anti-cancer
  • Other active . Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial. Please note: patients with more than 1 colorectal cancer tumor at diagnosis (as long as no stage IV disease) are allowed to participate. Pathologic response to each of the tumors will be examined
  • Active acute colonic obstruction. Patients whose obstruction is relieved by a successful defunctioning stoma are allowed once recovered to a fitness level consistent with the other eligibility criteria
  • uncontrolled illness
  • Females only: Pregnant or breastfeeding
  • Prior allergic reaction or to any of the study drug components
  • Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years before starting treatment, i.e., with use of disease-modifying agents or immunosuppressive drugs (excluding hypothyroidism, vitiligo, and psoriasis that is controlled with topical management)
  • History or current evidence of any condition, co-morbidity, therapy, that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator
  • Uncontrolled infection with (HIV). Patients on stable highly active antiretroviral therapy (HAART) are eligible. Serological testing for HIV at screening is not required
  • Uncontrolled infection with virus. Patients who are receiving or who have received anti-HBV therapy are eligible. Serological testing for HBV at screening is not required
  • Known active virus (HCV) as determined by positive serology and confirmed by polymerase chain reaction (PCR). Patients on or who have received antiretroviral therapy are eligible. Serological testing for HCV at screening is not required
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Treatment (botensilimab and balstilimab)

    Patients receive botensilimab IV, over 30 minutes, on day 1 and balstilimab IV, over 30 minutes, on days 1, 15, 29 and 43 in the absence of disease progression or unacceptable toxicity. 5-16 weeks later, patients then undergo standard of care resection surgery. Patients undergo CT scan and/or MRI and blood sample collection throughout the study.

    Biological: Balstilimab · Procedure: Biospecimen Collection · Biological: Botensilimab · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging

Interventions

  • BiologicalBalstilimab

    Given IV

    Also known as: AGEN 2034, AGEN-2034, AGEN2034

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • BiologicalBotensilimab

    Given IV

    Also known as: AGEN 1181, AGEN-1181, AGEN1181, Anti-CTLA-4 Monoclonal Antibody AGEN1181

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

06

What researchers measure

Primary outcomes

  1. Two-year disease-free survival rate

    Defined as the percentage of patients that remain free from any signs of colon cancer at two years post-enrollment. Will be compared to the historical control rate of 76.8% (from the FoXTROT adjuvant chemotherapy arm) using a one-sided, one-sample log-rank test.

    Time frame: At 2 years post enrollment

Secondary outcomes

  1. Major pathologic response rate

    Defined as the proportion of patients achieving major pathologic responses defined as either a \>= 90% tumor reduction or 100% reduction (near complete response + pathologic complete response). Will be compared with the historical control rate of 10% using a one-sided, continuity corrected Z-test.

    Time frame: Up to 3 years

  2. Incidence of adverse events

    Assessed according to Common Terminology Criteria for Adverse Events version 6.0. Will be summarized using descriptive statistics.

    Time frame: Up to 3 years

  3. Pathologic response rate

    Defined as the proportion of patients achieving a pathologic response, defined as a ≥ 50% tumor reduction.

    Time frame: Up to 3 years

  4. Three-year disease-free survival rate

    Defined as the percentage of patients that remain free from any signs of colon cancer at three years post-enrollment. Will be summarized similar to 2-year survival but at the 3-year mark.

    Time frame: At 3 years post-enrollment

  5. Recurrence free survival

    Assessed among patients that are disease free at the time of surgery. Will be graphically represented using Kaplan-Meier methods and summarized using descriptive statistics.

    Time frame: Time from surgery to date of first cancer recurrence or death as a result of any cause, whichever occurs first, up to 3 years

  6. Number of patients who get all four doses of balstilimab divided by number of enrolled patients

    Will be summarized using descriptive statistics.

    Time frame: Up to 3 months

  7. Change in Eastern Cooperative Oncology Group

    Will be summarized using descriptive statistics.

    Time frame: Up to 3 years

  8. Time to surgery

    Will be summarized using descriptive statistics.

    Time frame: Up to 9 months

  9. Proportion of patients in which adjuvant therapy is recommended, of these the percent who refuse adjuvant therapy

    Will be summarized using descriptive statistics.

    Time frame: Up to 9 months

07

Study locations

11 of 11 sites recruiting
  • CTCA at Western Regional Medical Center
    Goodyear, Arizona 85338, United States
    Recruiting
    • Pashtoon M. Kasi · Contactkasi@coh.org · 949-671-4673
    • Pashtoon M. Kasi · Principal investigator
  • City of Hope Corona
    Corona, California 92882, United States
    Recruiting
    • Pashtoon M. Kasi · Contactkasi@coh.org · 949-671-4673
    • Pashtoon M. Kasi · Principal investigator
  • City of Hope Medical Center
    Duarte, California 91010, United States
    Recruiting
    • Pashtoon M. Kasi · Contactkasi@coh.org · 949-671-4673
    • Pashtoon M. Kasi · Principal investigator
  • City of Hope Seacliff
    Huntington Beach, California 92648, United States
    Recruiting
    • Pashtoon M. Kasi · Contactkasi@coh.org · 949-671-4673
    • Pashtoon M. Kasi · Principal investigator
  • City of Hope at Irvine Lennar
    Irvine, California 92618, United States
    Recruiting
    • Pashtoon M. Kasi · Contactkasi@coh.org · 949-671-4673
    • Pashtoon M. Kasi · Principal investigator
  • City of Hope at Long Beach Elm
    Long Beach, California 90813, United States
    Recruiting
    • Pashtoon M. Kasi · Contactkasi@coh.org · 949-671-4673
    • Pashtoon M. Kasi · Principal investigator
  • City of Hope South Pasadena
    South Pasadena, California 91030, United States
    Recruiting
    • Pashtoon M. Kasi · Contactkasi@coh.org · 949-671-4673
    • Pashtoon M. Kasi · Principal investigator
  • City of Hope Upland
    Upland, California 91786, United States
    Recruiting
    • Pashtoon M. Kasi · Contactkasi@coh.org · 949-671-4673
    • Pashtoon M. Kasi · Principal investigator
  • City of Hope Atlanta Cancer Center
    Newnan, Georgia 30265, United States
    Recruiting
    • Pashtoon M. Kasi · Contactkasi@coh.org · 949-671-4673
    • Pashtoon M. Kasi · Principal investigator
  • City of Hope at Illinois Chicago Downtown
    Chicago, Illinois 60611, United States
    Recruiting
    • Pashtoon M. Kasi · Contactkasi@coh.org · 949-671-4673
    • Pashtoon M. Kasi · Principal investigator
  • City of Hope at Chicago
    Zion, Illinois 60099, United States
    Recruiting
    • Pashtoon M. Kasi · Contactkasi@coh.org · 949-671-4673
    • Pashtoon M. Kasi · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.

Of 123 non-industry phase 2 interventional studies under Colonic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 29 months is below that.

Counting every sponsor, half of 136 studies reached it within 43 months; a quarter within 30 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: start Dec 2026 → Jul 2026, primary completion May 2027 → Dec 2028 and completion May 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 19, 2026
StartActual
Jul 1, 2026was Dec 2026
Primary completionEst.
Dec 16, 2028was May 2027
CompletionEst.
Dec 16, 2028was May 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 27, 2026→Jul 1, 2026 (actual)
Oct 19, 2026
Primary completion
May 27, 2027→Dec 16, 2028
Oct 19, 2026
Study completion
May 27, 2027→Dec 16, 2028
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Start date Dec 27, 2026→Jul 1, 2026 (now actual)
    Primary completion May 27, 2027→Dec 16, 2028
    Study completion May 27, 2027→Dec 16, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07595874
Responsible party
Sponsor
First posted
May 19, 2026
Start date
Jul 1, 2026
Primary completion
Dec 16, 2028 (estimated)
Completion
Dec 16, 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Sebastian Perez
Contact
sebperez@coh.org
6262184357
Pashtoon M Kasi
principal investigator · City of Hope Medical Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Balstilimab · Botensilimab

Start the discussion